DNA
Your genetic blueprint and relevant mutations
Patients
Your Diagnosis May Be Shared.
Your Biology Is Not.
Two people can have the same diagnosis, exposure, virus, mutation, or symptoms—and still have very different biology driving their condition.
Neo7 looks deeper to identify what may be active in your body and uses those findings to design a personalized, multi-target peptide strategy.
Have We Been Asking the Wrong Question?
You may have been asking:
Was it a virus, Lyme, mold, bacteria, toxin, mutation, stress, or another exposure?
That may explain what started the problem. But it may not explain why it continues.
Neo7 Asks:
What is happening in your biology now that may be allowing illness to persist or progress?
What Is Neo7?
Neo7 is an N-of-1 precision approach. That means your analysis and therapy are designed around one patient—you.
We combine your symptoms, diagnosis, history, known mutations, current treatments, blood, and—depending on the program—urine to:
Measure several layers of active biology.
Find connected biological patterns.
Prioritize patient-specific targets.
Design a personalized, multi-target pooled peptide therapy.
Monitor and reassess as your biology changes.
Technology reveals the patterns. A multidisciplinary scientific and medical team determines what matters.
What Do We Evaluate?
Most laboratory panels examine one piece of the problem. Neo7 connects several.
Cancer signals
Circulating cancer-derived signals when applicable
RNA
What your genes appear to be doing now
Proteins and excretion
Functional activity and biological stress
HLA
How your immune system presents and recognizes targets
Which Neo7 Path Fits Me?
Four specialized precision therapeutic pathways
Cancer
Oncology PrecisionFor patients with active cancer or oncology‑focused precision needs.
- Blood and urine
- Five areas of analysis
- Commonly 10–14+ targets
- ≈10–11 weeks from samples to peptides
- Repeat testing 4–10 months
Active Disease
Complex ChronicFor autoimmune, inflammatory, neurological, vascular, metabolic, infectious, congenital, mitochondrial, and other complex conditions.
- Blood and urine
- Four areas of analysis
- Commonly 10–14+ targets
- ≈8–10 weeks from samples to peptides
- Repeat testing 8–10 months
Spike
Post‑Viral CareFor post‑viral or spike‑related biological dysregulation.
- Blood only—no urine required
- Six patient‑specific targets
- ≈6–7 weeks from blood draw to peptides
- Repeat testing 4–5 months
Resilience
Longevity & HealthFor prevention, longevity, cognition, energy, performance, and biological optimization.
- Blood and urine
- Four patient‑specific targets
- ≈6–7 weeks from samples to peptides
- Repeat testing 4–5 months
How Are My Targets Selected?
Neo7 does not simply target every abnormal result or choose the highest number on a laboratory report.
Our process considers:
- Your symptoms, concerns, and diagnosis
- Known mutations and treatment history
- The strength and relevance of each biological signal
- Connections across immune, inflammatory, neurological, vascular, metabolic, and other pathways
- Whether a target is therapeutically actionable
- Your individual HLA presentation
Advanced analytical pipelines, augmented intelligence, mathematical modeling, and statistical analysis help reveal patterns within complex data.
Those findings are reviewed by a multidisciplinary team that may include molecular PhDs, mathematicians, statisticians, pharmacists, geneticists, and medical providers.
Not an automated list of abnormalities. An expert-reviewed, N-of-1 target strategy.
What Are Your Outcomes?
No two patients begin at the same point.
Some patients come to Neo7 early, with limited disease and little previous treatment. Others arrive after multiple surgeries, medications, chemotherapy, radiation, immunotherapy, or integrative treatments. Some are medically stable; others have advanced or rapidly progressing disease.
Outcomes may also be affected by:
- Disease stage and burden
- Previous treatments
- Age, genetics, and organ function
- Nutrition, sleep, activity, and overall health
- Stress, trauma, and support
- Treatment timing and adherence
- Other therapies used alongside Neo7
Patients and providers have reported meaningful molecular, clinical, functional, and quality-of-life changes. Some patients have reached NED or NEAD, some have stabilized, some have experienced functional improvement, and some have required reassessment or redesign.
Another patient's experience cannot predict yours.
A patient story may show what is possible. It cannot promise what your biology will do.
Is Neo7 Based on My Diagnosis?
Your diagnosis helps define the clinical problem. It does not fully explain how that problem is operating within you.
Neo7 evaluates the biology beneath the diagnosis to identify the signals and relationships most relevant to your individual case.
Same diagnosis. Different biology. Different targets.
Have You Treated My Diagnosis?
Neo7 has worked with patients across cancer, chronic and complex disease, autoimmune conditions, post-viral and spike-related complications, and resilience goals.
But the more useful question is:
Can Neo7 evaluate the biology that may be driving my version of this condition?
The number of patients who share your diagnosis matters less than whether your active biological pattern can be evaluated and translated into an appropriate target strategy.
Is Neo7 a Miracle Cure?
No.
Neo7 is advanced personalized science—not a miracle claim, guaranteed outcome, or universal cure.
It is designed to identify patient-specific biological targets and create a personalized therapeutic strategy under licensed provider oversight.
What Is Treatment Like?
Treatment is individualized by your licensed prescriber.
Depending on your program and needs, administration may include:
- Subcutaneous injections
- Intramuscular injections
- Intravenous infusions when indicated
- Intranasal or nebulized delivery in selected cases
Many injections can be self-administered at home after training. Infusions require an appropriately licensed and equipped professional and may often be coordinated locally.
You generally do not have to travel to a central Neo7 facility.
Can I Be Managed Through Telemedicine?
Yes, when provider licensing and applicable requirements allow.
Telemedicine may be used for consultation, prescribing, education, report review, and follow-up. Blood and urine collection and any required infusions can often be coordinated through local resources.
A licensed prescriber is required.
Do I Have to Stop Anything Before Testing?
No routine medication, supplement, peptide, chemotherapy, immunotherapy, or integrative-treatment washout is required solely for Neo7 collection.
Document everything you are currently taking or receiving. Never stop prescribed treatment unless the clinician managing it instructs you to do so.
What Side Effects Should I Expect?
Because each therapy and patient are different, a website cannot predict exactly how you will feel.
Neo7 uses a personalized, HLA-informed, low-and-slow implementation strategy. Neo7 reports no serious adverse effects through its program since 2019, but this does not mean side effects are impossible or that every patient has the same risk.
Report new, worsening, or concerning symptoms to your prescribing provider. Do not assume feeling worse means the therapy is working.
Why Might I Need Repeat Testing?
Biology changes.
Disease may respond, adapt, develop new mutations, or shift to different signaling pathways. Repeat testing can show whether the original targets remain relevant or whether the strategy should be refined.
The ability to reassess and adapt is part of personalization—not necessarily evidence that the first strategy failed.
Does Neo7 Replace My Other Treatments?
No. Neo7 is a both-and approach, not an automatic either-or decision.
Your provider remains at the center of your care and determines which therapies are appropriate. Your coordinated plan may include:
- Surgery, chemotherapy, radiation, or immunotherapy
- Prescription medications
- Antiviral, antibiotic, or antifungal treatment
- Other immune-directed approaches
- Integrative therapies
- Nutrition, rehabilitation, movement, and lifestyle support
- Neo7's personalized biological strategy
Neo7 is one part of the hub strategy—not the whole wheel.
Never stop or delay prescribed treatment without direction from the clinician managing it.
How Will We Know Whether I Am Responding?
Your provider may evaluate several parts of your clinical picture:
Symptoms and quality of life
Strength, stamina, mobility, cognition, or pain
Laboratory findings
Imaging
Cancer markers
ctDNA or other molecular findings
Circulating tumor cells when appropriate
Neo7 surveillance and reassessment tools
How you feel matters—but it should not be interpreted separately from the biological and clinical evidence.
FAQs
No. Genetics may show what is present or possible. Neo7 also evaluates what may be actively happening through RNA expression, proteins, excretion, immune presentation, clinical context, and cancer-derived signals when applicable.
No. Targets are prioritized from your individual analysis before your pooled peptide therapy is designed.
No. Stacked protocols usually combine existing peptides based on a diagnosis, symptom, or goal. Neo7 begins with patient-specific biological targets.
No. Neo7 uses a coordinated, multi-target strategy because complex disease rarely operates through one isolated signal.
No. Neo7 does not edit or permanently alter your genes.
Neo7 is not designed as an immunosuppressive therapy. Its target strategy is personalized and HLA-informed.
Neo7 is not an off-the-shelf preventive vaccine. It is a personalized pooled peptide therapy designed from the individual patient’s findings.
Yes. A licensed prescriber is required to determine appropriateness, prescribe therapy, direct implementation, and monitor your care.
Yes, if your provider is willing and able to complete Neo7 onboarding and meet applicable prescribing requirements.
Neo7 may help connect you with an appropriate provider or discuss onboarding with a qualified provider you already know.
No. Testing is part of an integrated program that includes analysis, target prioritization, reporting, personalized design, implementation planning, monitoring, and reassessment.
Raw data are not provided as a stand-alone deliverable. The prescribing provider receives the clinical report and relevant target findings for review with you.
Outside results provide valuable clinical context, but they generally do not replace the program-specific samples needed for current personalized analysis and design.
Follow the collection instructions included with your order and any additional directions from your provider or collection site.
Often, yes. Many subcutaneous or intramuscular injections can be administered at home after proper training.
Possibly. Home infusion availability depends on provider orders, local resources, safety requirements, and your condition. A local clinic or infusion center may also be used.
Often, yes. Discuss medication storage, supplies, dosing, time zones, documentation, and infusion scheduling with your provider before traveling.
Do not double your next dose unless your prescriber instructs you to do so. Contact your provider for guidance.
Duration depends on the pathway, disease burden, response, dosing, other treatments, and reassessment findings. Spike and Resilience are often approximately six months. Cancer and Active Disease programs may continue longer.
There is no universal response time. Symptoms, function, laboratory findings, imaging, and molecular changes may improve on different timelines.
Contact your prescribing provider. Worsening should not automatically be described as healing, detoxification, or proof of response.
Neo7 should not be viewed as a universal stand-alone treatment. Whether it is used alone or with other care depends on your condition, disease burden, urgency, goals, stability, and provider judgment.
Neo7 therapies are individualized N-of-1 designs prescribed and overseen by licensed providers within an IRB-governed framework. They are not presented as standardized FDA-approved drug products.
An Institutional Review Board provides ethical and procedural oversight intended to help protect participants. IRB oversight does not guarantee safety, effectiveness, or an individual result.
No. Neo7 and routine telemedicine are not emergency services. Seek urgent local medical care for severe or rapidly worsening symptoms.
Ready to Ask a Better Question?
Your diagnosis tells us what your condition is called.
Your biology may help explain why it is behaving the way it is.
Call the Neo7Bioscience main office or inquire online to discuss whether one of the Neo7 pathways may be appropriate for your case.